



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Bruce Hay et al. :

APPLICATION NO.: Express Mail Label No.
EL625565115US

: Examiner: Andrea D. Small
(anticipated)

FILING DATE: November 16, 2001

: Group Art Unit: 1626
(anticipated)

TITLE: SOMATOSTATIN ANTAGONISTS AND
AGONISTS THAT ACT AT THE SST
SUBTYPE 2 RECEPTOR

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.


It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: _____

11/16/01

Respectfully submitted,



E. Victor Donahue
Attorney for Applicant(s)
Reg. No. 35,492

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-2739

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC10720B				SERIAL NO. Not Assigned			
				APPLICANT Bruce Hay et al.							
				FILING DATE November 16, 2001				GROUP Not Assigned			

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	US	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5	9	3	6	0	8	9	8/10/99	Carpino, et al.			

FOREIGN PATENT DOCUMENTS															
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
													YES	NO	
		WO	99/	6	4	4	0	1	12/16/99	PCT/US					
		WO	98/	4	4	9	2	2	10/15/98	PCT/US					
		WO	98/	4	5	2	8	5	10/15/98	PCT/US					
		WO	99/	6	4	4	2	0	12/16/99	PCT/US					
		WO	98/	4	4	9	2	1	10/15/98	PCT/US					

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>													
		Sadaf Farooqu et al., "The Therapeutic Value of Somastatin and Its Analogues" <i>Pituitary</i> Vol. 2, pp. 79-88 (1999)											
		Susan P. Rohrer, et al., "Rapid Identification of Subtype-Selective Agonists of the Somatostatin Receptor Through Combinatorial Chemistry" <i>Science</i> Vol. 282, pp. 737-740; (1998)											
		Henning Grønbaek, et al. "Potential Role of Octreotide in the Treatment of Diabetes" <i>Prog Basic Clin Pharmacol. Basel</i> , vol. 10, pp. 103-128; (1996)											
		Vicente Martinez, et al., "High Basal Gastric Acid Secretions in Somatostatin Receptor Subtype 2 Knockout Mice"; <i>American Gastroenterology</i> (1998) 114 pp. 1125-1132											
		Yogesh C. Patel, et al., "Somatostatin Receptors", <i>TEM</i> , Vol. 8, No. 10, (1997) pages 398-404											
		Lihu Yang, et al., "Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2"; <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 10836-10841, (1998)											
		Simon J. Hocart, et al., "Potent Antagonists of Somatostatin: Synthesis and Biology"; <i>J. Med. Chem.</i> Vol. 41, pp. 1146-1154											
		Muhammad Zaki, et al., "Somatostatin Receptor Subtype 2 Mediates Inhibition of Gastrin and Histamine Secretion from Human, Dog and Rat Antrum"; <i>Gastroenterology</i> Vol. 111, pp. 919-924 (1996)											
		William R. Baumbach, et al., "A Linear Hexpeptide Somatostatin Antagonist Blocks Somatostatin Activity In Vitro and Influences Growth Hormone Release in Rats" <i>Molecular Pharmacology</i> , Vol. 54, pp.864-873 (1998)											

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO. PC10720B				SERIAL NO. Not Assigned			
				APPLICANT Bruce Hay et al.							
				FILING DATE November <u>16</u> , 2001				GROUP Not Assigned			

U.S. PATENT DOCUMENTS															
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		

11/28/01
 09/997479
 U.S. PRO
 1050

FOREIGN PATENT DOCUMENTS																
DOCUMENT NUMBER										DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
														YES	NO	
		WO	99/	2	2	7	3	5	5/14/99		PCT/US					

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
			Lihu Yang, et al., "Spiro[1H-indene-1,4-piperidine]Derivatives as Potent and Selective Non-Peptide Human Somatostatin Receptor Subtype 2 (SST2) Agonists", <i>Journal of Medicinal Chemistry</i> , vol. 41, no. 13, pp. 2175-2179 (1998)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.